Corium International, Inc. (NASDAQ:CORI)‘s stock had its “buy” rating restated by stock analysts at Jefferies Group LLC in a research report issued to clients and investors on Monday. They presently have a $10.00 price target on the biopharmaceutical company’s stock. Jefferies Group LLC’s target price points to a potential upside of 28.04% from the stock’s previous close.

Several other equities analysts have also weighed in on CORI. BidaskClub lowered shares of Corium International from a “buy” rating to a “hold” rating in a research report on Thursday. Zacks Investment Research lowered shares of Corium International from a “buy” rating to a “hold” rating in a research report on Tuesday, July 11th. ValuEngine raised shares of Corium International from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. WBB Securities upgraded shares of Corium International to a “buy” rating and set a $13.00 price target on the stock in a research note on Friday, July 7th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $12.00 price target (up from $10.00) on shares of Corium International in a research note on Friday, May 12th. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $11.79.

Shares of Corium International (CORI) opened at 7.81 on Monday. The firm’s market capitalization is $228.30 million. The firm has a 50-day moving average of $8.17 and a 200 day moving average of $5.48. Corium International has a 52-week low of $2.67 and a 52-week high of $9.57.

Corium International (NASDAQ:CORI) last issued its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.43) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by $0.13. The company had revenue of $8.11 million during the quarter, compared to the consensus estimate of $8.71 million. Corium International had a negative net margin of 145.60% and a negative return on equity of 1,550.00%. Analysts predict that Corium International will post ($1.62) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This news story was posted by Daily Political and is the property of of Daily Political. If you are accessing this news story on another website, it was stolen and republished in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.dailypolitical.com/2017/08/07/jefferies-group-llc-reiterates-buy-rating-for-corium-international-inc-nasdaqcori.html.

In other Corium International news, major shareholder Life Sciences Maste Perceptive purchased 301,004 shares of the firm’s stock in a transaction that occurred on Friday, June 30th. The shares were acquired at an average cost of $7.71 per share, for a total transaction of $2,320,740.84. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Perceptive Advisors Llc purchased 1,902,400 shares of the firm’s stock in a transaction that occurred on Thursday, May 25th. The stock was acquired at an average price of $6.25 per share, for a total transaction of $11,890,000.00. The disclosure for this purchase can be found here. Corporate insiders own 45.70% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the stock. Perceptive Advisors LLC purchased a new stake in shares of Corium International during the first quarter worth about $11,096,000. AWM Investment Company Inc. increased its stake in shares of Corium International by 1,125.9% in the first quarter. AWM Investment Company Inc. now owns 2,451,700 shares of the biopharmaceutical company’s stock worth $10,248,000 after buying an additional 2,251,700 shares during the last quarter. Broadfin Capital LLC increased its stake in shares of Corium International by 45.2% in the first quarter. Broadfin Capital LLC now owns 2,787,121 shares of the biopharmaceutical company’s stock worth $11,650,000 after buying an additional 867,400 shares during the last quarter. Royce & Associates LP increased its stake in shares of Corium International by 208.4% in the first quarter. Royce & Associates LP now owns 548,464 shares of the biopharmaceutical company’s stock worth $2,293,000 after buying an additional 370,600 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its stake in shares of Corium International by 161.8% in the second quarter. Bank of New York Mellon Corp now owns 66,160 shares of the biopharmaceutical company’s stock worth $494,000 after buying an additional 40,891 shares during the last quarter. Institutional investors and hedge funds own 77.81% of the company’s stock.

About Corium International

Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.

Analyst Recommendations for Corium International (NASDAQ:CORI)

Receive News & Ratings for Corium International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.